Neurotransmitter CART as a New Therapeutic Candidate for Parkinson’s Disease
AbstractParkinson’s disease (PD) is one of the most common neurodegenerative diseases. To date, there is no effective treatment that halts its progression. Increasing evidence indicates that mitochondria play an important role in the development of PD. Hence mitochondria-targeted approaches or agents may have therapeutic promise for treatment of the disease. Neuropeptide CART (cocaine-amphetamine-regulated transcript), a hypothalamus and midbrain enriched neurotransmitter with an antioxidant property, can be found in mitochondria, which is the main source of reactive oxygen species. Systemic administration of CART has been found to ameliorate dopaminergic neuronal loss and improve motor functions in a mouse model of PD. In this article, we summarize recent progress in studies investigating the relationship between CART, dopamine, and the pathophysiology of PD, with a focus on mitochondria-related topics. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Mao, P.; Meshul, C.K.; Thuillier, P.; Reddy, P.H. Neurotransmitter CART as a New Therapeutic Candidate for Parkinson’s Disease. Pharmaceuticals 2013, 6, 108-123.
Mao P, Meshul CK, Thuillier P, Reddy PH. Neurotransmitter CART as a New Therapeutic Candidate for Parkinson’s Disease. Pharmaceuticals. 2013; 6(1):108-123.Chicago/Turabian Style
Mao, Peizhong; Meshul, Charles K.; Thuillier, Philippe; Reddy, P. H. 2013. "Neurotransmitter CART as a New Therapeutic Candidate for Parkinson’s Disease." Pharmaceuticals 6, no. 1: 108-123.